Research ArticleTheranostics
Proof of Therapeutic Efficacy of a 177Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model
Jörg Schulz, Martin Rohracker, Marvin Stiebler, Jürgen Goldschmidt, Franziska Stöber, Mercedes Noriega, Anette Pethe, Mathias Lukas, Frank Osterkamp, Ulrich Reineke, Aileen Höhne, Christiane Smerling and Holger Amthauer
Journal of Nuclear Medicine June 2017, 58 (6) 936-941; DOI: https://doi.org/10.2967/jnumed.116.185140
Jörg Schulz
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität, Magdeburg, Germany
Martin Rohracker
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität, Magdeburg, Germany
Marvin Stiebler
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität, Magdeburg, Germany
Jürgen Goldschmidt
2Leibniz-Institut für Neurobiologie, Magdeburg, Germany
Franziska Stöber
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität, Magdeburg, Germany
2Leibniz-Institut für Neurobiologie, Magdeburg, Germany
Mercedes Noriega
3Institut für Pathologie, Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany
Anette Pethe
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität, Magdeburg, Germany
Mathias Lukas
4Department of Nuclear Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany
5Siemens Healthcare GmbH, Erlangen, Germany; and
Frank Osterkamp
63B Pharmaceuticals GmbH, Berlin, Germany
Ulrich Reineke
63B Pharmaceuticals GmbH, Berlin, Germany
Aileen Höhne
63B Pharmaceuticals GmbH, Berlin, Germany
Christiane Smerling
63B Pharmaceuticals GmbH, Berlin, Germany
Holger Amthauer
1Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke Universität, Magdeburg, Germany
4Department of Nuclear Medicine, Charité–Universitätsmedizin Berlin, Berlin, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 6
June 1, 2017
Proof of Therapeutic Efficacy of a 177Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model
Jörg Schulz, Martin Rohracker, Marvin Stiebler, Jürgen Goldschmidt, Franziska Stöber, Mercedes Noriega, Anette Pethe, Mathias Lukas, Frank Osterkamp, Ulrich Reineke, Aileen Höhne, Christiane Smerling, Holger Amthauer
Journal of Nuclear Medicine Jun 2017, 58 (6) 936-941; DOI: 10.2967/jnumed.116.185140
Proof of Therapeutic Efficacy of a 177Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model
Jörg Schulz, Martin Rohracker, Marvin Stiebler, Jürgen Goldschmidt, Franziska Stöber, Mercedes Noriega, Anette Pethe, Mathias Lukas, Frank Osterkamp, Ulrich Reineke, Aileen Höhne, Christiane Smerling, Holger Amthauer
Journal of Nuclear Medicine Jun 2017, 58 (6) 936-941; DOI: 10.2967/jnumed.116.185140
Jump to section
Related Articles
Cited By...
- Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism
- Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted {alpha}-particle therapy
- Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review
- Genetic signature of prostate cancer resistant to optimized hK2 targeted alpha-particle therapy
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- 177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results
- NTR Is the New SSTR? Perspective for Neurotensin Receptor 1 (NTR)-Directed Theranostics